CMS Expands Medicare Part D Coverage to GLP-1 Agonists for Obesity Effective October 2024

The Centers for Medicare & Medicaid Services updated guidance to allow Part D plans to reimburse semaglutide and tirzepatide for obesity when prescribed without a diabetes diagnosis. This reverses prior restrictions that limited coverage to Type 2 diabetes, obstructive sleep apnea, or established cardiovascular disease. Plans must now process claims under the new criteria, with beneficiary cost-sharing capped at standard formulary tiers rather than full out-of-pocket pricing.

Federal spending data show GLP-1 utilization already reached 3.4 million Medicare beneficiaries in 2023 under diabetes indications, generating $12.8 billion in gross drug costs. Extending eligibility to the estimated 15 million obese beneficiaries without those comorbidities projects an incremental $30-45 billion annual outlay once uptake stabilizes. The change aligns with the SELECT trial results demonstrating 20 percent relative reduction in major adverse cardiovascular events, which the agency cites to justify long-term savings against obesity-related claims.

The ledger records two direct effects. Medicare gains potential downstream reductions in hospitalizations for heart failure and stroke, while manufacturers secure a stable, volume-driven revenue stream insulated from prior coverage denials. Offsetting costs include immediate pressure on the Part D trust fund and upward price negotiation leverage under the Inflation Reduction Act, which now applies to these products. No statutory change occurred; the shift rests on reinterpretation of existing obesity management authorities.

Next reporting cycles will reveal whether plans impose prior authorization or step therapy that limits actual utilization below projected volumes. CMS will publish 2025 enrollment and claims data by June 2026, providing the first measurable test of net fiscal impact.